taglidine
Small moleculeexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
2
Phase 4
3
Earliest trial started Mar 3, 2021 (NCT04766463)
Timeline
Indications
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229495 | Phase 4 | Jan 1, 2026 | Chinese Academy of Medical Sciences |
| NCT07277153 | Phase 4 | Oct 18, 2025 | Hainan Medical College |
| NCT07096115 | N/A | Sep 1, 2025 | The First People's Hospital of Lianyungang |
| NCT06458400 | Phase 4 | Jun 6, 2024 | Jiao Tong University |
| NCT07189962 | Phase 1 | Sep 20, 2022 | Hengrui Therapeutics, Inc. |
| NCT05470049 | Phase 2 | Aug 1, 2022 | Hengrui Therapeutics, Inc. |
| NCT05375305 | Phase 2 | May 15, 2022 | Hengrui Therapeutics, Inc. |
| NCT05928988 | Phase 1 | Jan 4, 2022 | Hengrui Therapeutics, Inc. |
| NCT04794738 | Phase 2/Phase 3 (Phase 3) | Apr 18, 2021 | Hengrui Therapeutics, Inc. |
| NCT04766463 | Phase 3 | Mar 3, 2021 | Hengrui Therapeutics, Inc. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 6 | 6 | 3 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Hainan Medical College | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| The First People's Hospital of Lianyungang | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1